default author photo

Christopher R. Flowers

University of Texas at Houston - Department of Lymphoma and Myeloma

Houston, TX

United States

SCHOLARLY PAPERS

4

DOWNLOADS

171

TOTAL CITATIONS

0

Scholarly Papers (4)

1.

Safety and Activity of Lenalidomide in Combination with Obinutuzumab in Patients with Relapsed Indolent Non-Hodgkin Lymphoma: A Single Group, Open-Label, Phase 1/2 Trial

Number of pages: 42 Posted: 08 Apr 2024
University of Texas at Houston, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma and University of Texas at Houston - Department of Lymphoma and Myeloma
Downloads 75 (837,727)

Abstract:

Loading...

Follicular Lymphoma, B-Cell Lymphoma, Lenalidomide, Therapeutic Use, Obinutuzumab, Antineoplastic Agents, Immunological

2.

Rewiring BCL6 with Transcriptional/epigenetic Chemical Inducers of Proximity Unveils Targetable Plasticity in Large B Cell Lymphoma

Number of pages: 61 Posted: 16 Jun 2026
University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, Stanford University, Stanford University, University of Texas at Houston - Department of Lymphoma and Myeloma, Stanford University, Stanford University, University of Texas at Houston - Graduate School of Biological Sciences, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, Stanford University, Stanford University, Stanford University, Stanford University, Stanford University, Stanford University, Stanford University, Stanford University, Stanford University, Stanford University, University of Texas at Houston - Department of Lymphoma and Myeloma, Mayo Clinic, Emory University, Cornell University - Pathology and Laboratory Medicine, UT MD Anderson Cancer Center, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - MD Anderson Cancer Center, Stanford University - Howard Hughes Medical Institute, Stanford University - Department of Chemical and Systems Biology, University of Texas at Houston - Department of Lymphoma and Myeloma and Independent
Downloads 36

Abstract:

Loading...

Lymphoma, BCL6, epigenetics, plasticity

3.

Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy

Number of pages: 37 Posted: 09 Nov 2022
University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma/Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Lymphoma and Myeloma, University of Texas at Houston - Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, University of Texas at Houston - Department of Lymphoma and Myeloma and University of Texas at Houston - Department of Lymphoma and Myeloma
Downloads 33 (1,277,121)

Abstract:

Loading...

CAR T-cell, B-cell lymphoma, Cytopenia, Interferon

4.

Clinical Outcomes and Patterns of Care Among Patients with Newly Diagnosed Hodgkin Lymphoma in a Safety-Net Health System

Number of pages: 21 Posted: 04 Jun 2025
affiliation not provided to SSRN, affiliation not provided to SSRN, Baylor College of Medicine, affiliation not provided to SSRN, Baylor University - Section of Epidemiology and Population Sciences, Baylor University - Section of Epidemiology and Population Sciences, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Baylor College of Medicine, affiliation not provided to SSRN, University of Texas at Houston - Department of Lymphoma and Myeloma, Baylor University - Section of Hematology-Oncology and affiliation not provided to SSRN
Downloads 27 (1,359,097)

Abstract:

Loading...

Hodgkin lymphoma, health disparity, outcomes research